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ABSTRACT 
Preoperative anaemia is common in the Asia-Pacific. Iron-deficiency anaemia (IDA) is a risk 
factor that can be addressed under patient blood management (PBM) Pillar 1, leading to 
reduced morbidity and mortality. We examined PBM implementation under four different 
healthcare systems, identified challenges and proposed several measures. (a) Test for anaemia 
once patients are scheduled for surgery. (b) Inform patients about risks of preoperative anaemia 
and benefits of treatment. (c) Treat IDA and replenish iron stores before surgery, using 
intravenous iron when oral treatment is ineffective, not tolerated or rapid iron replenishment is 
needed; transfusion should not be the default management. (d) Harness support from multiple 
medical disciplines and relevant bodies to promote PBM implementation. (e) Demonstrate 
better outcomes and cost savings from reduced mortality and morbidity. Although PBM 
implementation may seem complex and daunting, it is feasible to start small. Implementing 
PBM Pillar 1, particularly in preoperative patients, is a sensible first step regardless of the 
healthcare setting.  
 
Keywords: anaemia, Asia Pacific, iron deficiency, patient blood management, Pillar 1
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INTRODUCTION  
Anaemia is a global health problem, affecting 30% of the world’s population in 2015.(1) In 
2010, there were 68.4 million years lived with disability from anaemia worldwide, and 56% of 
these were in Asia-Pacific countries.(2) Anaemia, which is characterised by a decrease in total 
red blood cell (RBC) mass, is accompanied by reduced haemoglobin (Hb) levels and altered 
RBC morphology. As its symptoms are nonspecific and develop gradually, it often goes 
unnoticed and therefore untreated. Iron deficiency (ID) is the most common cause of anaemia 
(> 50%),(2) manifesting in decreased production of Hb and activity of iron-dependent 
enzymes.(3) Iron deficiency anaemia (IDA) often presents in young children and pregnant 
women in developing countries due to malnutrition, multiparity, postpartum haemorrhage and 
infectious diseases; and in the elderly due to bleeding from gastrointestinal conditions.(4) 
 Preoperative anaemia represents a significant healthcare problem in Asia-Pacific 
countries.(5-8) This is compounded by the limited supply of blood products: 19 (23%) out of 82 
countries with low donation rates (< 10 donations per 1,000 population) are in the Asia-
Pacific.(9) These are typically developing countries with growing populations and a high 
demand for transfusions.(10) Their blood services also face difficulties in safeguarding blood 
stocks from risks posed by pathogens in the blood supply.(11) On the other hand, the developed 
countries, and even some of the less developed countries with ageing populations, have to 
confront the decreasing numbers of eligible donors. In addition, older persons, who have higher 
risks of malignancies and chronic diseases, are more likely to require complex surgical 
interventions.(12)  
 
POORER OUTCOMES FOR PATIENTS WITH PREOPERATIVE ANAEMIA 
IDA is an independent risk factor for poor outcomes among patients scheduled for surgery. In 
a meta-analysis of observational studies, 39.1% of 949,445 patients undergoing surgery were 
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found to be anaemic.(13) This study and others (Table I) found preoperative anaemia to be 
associated with greater risks of transfusion, morbidity, mortality and increased hospital length 
of stay (LOS).(5,8,14-19) Despite these risks and the exacerbation of anaemia by surgical blood 
loss, preoperative anaemia is deemed acceptable by many physicians.(20) Consequently, many 
patients receive allogeneic RBC transfusions, which have remained the mainstay of 
perioperative anaemia management in many settings. This may be undesirable, as RBC 
transfusion is another independent risk factor for adverse outcomes such as infections and lung 
injury.(21) 
 
Table I. Outcomes in patients with preoperative anaemia. 
No. Study, yr Description Results 
1 Non-cardiac 
surgery, 
2018(15) 
Retrospective analysis of 
medical records of 24,579 
patients aged ≥ 65 years in 
Singapore (January 2012–
October 2016) 
Moderate/severe anaemia vs. 
normal: 
 30-day mortality adjusted 
OR 1.61 (95% CI 1.03–2.52); p 
= 0.04 
2 Cardiac and 
non-cardiac 
surgery, 
2017(8) 
Retrospective review of 
97,443 patients in Singapore 
(January 2012–October 
2016) 
Anaemia prevalence 27.8% 
(mild anaemia 15.3%, 
moderate anaemia 12.0%, 
severe anaemia 0.5%) 
Moderate/severe anaemia vs. 
normal: 
 1-year mortality-adjusted HR 
2.86 (95% CI 2.56–3.20) 
Mild anaemia vs. normal: 
 1-year mortality-adjusted HR 
1.98 (95% CI 1.77–2.21) 
3 Primary total 
knee 
arthroplasty, 
2017(14)  
Retrospective study of 2,394 
patients in Singapore 
(January 2013–June 2014) 
Anaemia prevalence 23.7%: 
403 (16.8%) with mild 
anaemia and 164 (6.8%) 
with moderate-to-severe 
anaemia. 
Moderate-to-severe anaemia vs. 
normal: 
 LOS OR 3.22 (95% CI 2.29–
4.53); p < 0.001 
Mild anaemia vs. normal:  
 LOS OR 1.97 (95% CI 1.53–
2.53); p = 0.001 
4 Orthopaedic 
surgery, 
2015(17) 
Observational study of 1,534 
patients from 17 centres in 6 
European countries 
Preoperative anaemia 
prevalence 14.1%, 
postoperative anaemia 
prevalence 85.8% 
Preoperative anaemia vs. non-
anaemic: 
 Transfusion: 14.8% vs. 2.8%  
 Units per patient: 2.4 (1.5) 
vs. 2.2 (1.4) 
 Median time (min) to first 
intraoperative transfusion: 
130 (range 88–158) vs. 179 
(range 135–256); p < 0.001 
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 Postoperative complications: 
36.9% vs. 22.2%; p = 0.009  
4 Inpatient 
surgery, 
2014(16) 
Retrospective study of 
39,309 patients in 28 
European nations 
Preoperative anaemia vs. 
normal Hb concentrations: 
 Mortality for severe (odds 
ratio 2.82 [95% CI 2.06–3.85]) 
or moderate (1.99 [95% CI 
1.67–2.37]) anaemia higher 
than those with normal 
preoperative Hb concentrations  
 LOS (p < 0.001)  
 Postoperative admission to 
intensive care (p < 0.001)  
4 Gynaecological 
surgery, 
2013(5) 
Retrospective study of 843 
women in Western Australia 
undergoing major 
gynaecological surgery over 
a two-year period 
Preoperative anaemia 
present in 18.1% of women 
Preoperative anaemia vs. 
without anaemia: 
 Transfusion: OR 5.74, p < 
0.001  
No increased complications or 
LOS 
5 Major non-
cardiac 
surgery, 
2011(18) 
Retrospective study of 
227,425 patients undergoing 
major non-cardiac surgery in 
United States, of whom 
69,229 (30.44%) had 
preoperative anaemia 
Preoperative anaemia vs. 
without anaemia: 
 Postoperative mortality at 30 
days: OR 1.42 (95% CI 1.31–
1.54) 
Mild anaemia: OR 1.41 (95% 
CI 1.30–1.53)  
Moderate-to-severe anaemia: 
OR 1.44 (95% CI 1.29–1.60) 
 Composite postoperative 
morbidity at 30 days: OR 1.35 
(95% CI 1.30–1.40) 
Mild anaemia: OR 1.31 (95% 
CI 1.26–1.36) 
Moderate-to-severe anaemia: 
OR 1.56 (95% CI 1.47–1.66) 
6 Hip and knee 
surgery, 
2010(19) 
Systematic review of 49 
published studies in 
MEDLINE on anaemia (but 
not sickle cell) in patients 
undergoing (1) total hip or 
knee arthroplasty and (2) hip 
fracture surgery 
Preoperative anaemia: 24% 
(hip/knee arthroplasty) and 
44% (hip fracture) 
Perioperative anaemia:
 Transfusion rate of 45% ± 
25% and 44% ± 15% 
 Postoperative anaemia: 51% 
and 87% 
 Postoperative infections, 
poorer physical functioning and 
recovery, and increased LOS 
and mortality 
CI: confidence interval; Hb: haemoglobin; HR: hazard ratio; LOS: length of hospital stay; 
OR: odds ratio; rHuEPO: recombinant human erythropoietin 
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Patient blood management (PBM) improves patient outcomes by applying evidence-
based medical and surgical concepts across its three pillars, namely: Pillar 1 – optimise RBC 
mass; Pillar 2 – minimise blood loss; and Pillar 3 – optimise anaemia tolerance of the patient 
to improve outcomes by clinically managing and preserving the patient’s own blood.(22) In May 
2010, the World Health Organization (WHO) formally recognised the importance of PBM and 
recommended it to its 193 member states.(23) Under PBM Pillar 1, a key strategy for optimising 
the total RBC mass of patients undergoing surgery is to identify anaemia and treat its 
underlying causes preoperatively.(22) For example, the Australian PBM guidelines recommend 
that doctors perform early evaluation and treatment of preoperative ID/IDA and its underlying 
causes as part of preparation for elective surgery.(24) In most cases, preoperative IDA can be 
corrected with iron replacement therapy.(22)  
Successful PBM implementation in Western Australia was associated not only with 
reduced blood use (i.e. RBC units/admission declined by 26% despite a 22% rise in 
admissions)(25) but also significant reductions in preoperative anaemia, hospital-acquired 
complications, in-hospital mortality and LOS, with cost savings of > AUD 6 million per 
year.(26) Such observations give weight to recommendations that elective surgeries be delayed 
until after anaemia correction.(27) Despite these reasons and the availability of therapeutic 
strategies and pharmacologic interventions for reducing transfusion in the perioperative setting, 
PBM implementation has varied widely, even in Europe and Canada where PBM has been 
practised for many years.(28,29)  
 
CHALLENGES AND PROPOSED SOLUTIONS 
We examined PBM implementation in the Asia-Pacific countries of Australia, Malaysia, 
Republic of Korea and Singapore, discussing specific challenges of implementing PBM in 
these countries and suggesting potential solutions (Table II). 
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Table II. Challenges to PBM implementation and proposed solutions. 
Challenge Reason/perception Recommendation 
Physicians do not 
want to postpone 
surgery in order to 
treat anaemia 
They cannot make a patient 
wait for 2–3 weeks to receive 
treatment for IDA. There is a 
fear of complications from 
delayed surgery. 
 
 
Elective surgeries are usually 
scheduled in advance. The referring 
primary care doctor could exclude 
anaemia or treat the anaemia 
appropriately, if present, or the 
surgeon could check for anaemia and 
treat as soon as the patient is 
scheduled for surgery. This allows 
sufficient time for investigation of 
the underlying cause and appropriate 
management. 
Physician support Scepticism about efficacy of 
PBM, unease with procedural 
scrutiny and an ingrained 
belief that transfusion is safe. 
 Champions are needed within 
each discipline to promote PBM 
from the patient safety 
perspective. Interdisciplinary 
collaboration between various 
stakeholder disciplines, such as 
the blood transfusion committee 
working together with clinical 
departments, is essential to 
effective implementation.  
 Focus on efforts to implement 
PBM to provide the best patient 
care rather than deliverables. A 
result-oriented approach may 
invite resistance from physicians.  
Limited time prior 
to surgery for IDA 
correction. 
Hospital 
administration is 
concerned about 
underutilisation of 
operating theatre 
resources, as they 
cannot be re-
allocated at short 
notice.  
 
 Rescheduling a patient for 
surgery may create a 
problem that the operating 
room time slot may not be 
utilised by another patient 
due to the short notice.   
 For patients requiring 
chemotherapy and 
surgery, there is a short 
window period prior to 
surgery and 2 weeks may 
not be sufficient. 
 Iron studies can be performed at 
pre-admission assessment and 
treatment given for underlying 
causes, if needed, to avoid 
additional visits or rescheduling.  
 Intravenous iron can be given on 
the day before surgery or in 
operating rooms if time is 
severely limited. Transfusion 
alone is insufficient to replenish 
drained iron stores.  
Additional patient 
visits for iron 
supplementation 
result in more costs 
for patient. 
 Patients may be 
inconvenienced by 
additional visits for iron 
studies and iron therapy, 
e.g. patients who travel 
out of town for surgery. 
 Patients need to be informed 
about the risks of preoperative 
anaemia; and that with treatment, 
he/she can get home sooner after 
an operation. 
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Iron studies may 
add to the cost of 
treatment 
 
 In some countries, the 
government bears the cost 
of iron studies. Hospital 
administration wants to 
see cost ‘savings’. 
 Blood is sometimes 
perceived to be readily 
available at reasonable 
costs or even ‘free’. 
 Help the government and 
hospital administration see 
savings in terms of reduction in 
mortality, morbidity, RBC 
transfusion and length of stay.  
 The government or hospital may 
already be subsidising the cost of 
blood. The actual cost of 
providing blood should be made 
known. 
 
Availability of iron 
studies 
Some iron studies are not 
readily available at hospitals. 
A ferritin assessment (< 100 μg/L) 
should be sufficiently sensitive to 
detect most IDA cases. Assess 
clinical and patient-specific risk 
factors concurrently, as this also 
helps to determine the likely cause 
and guide the management of 
anaemia, especially in the absence of 
resources for timely iron status 
evaluation. 
Other clinical 
considerations 
 In cancer patients with 
IDA (5–7 g/dL), ferritin 
may be as high as 500 
μg/L.  
 For renal failure patients, 
it is not recommended to 
raise Hb above 12 g/dL 
with erythropoietin-
stimulating agents, to 
reduce risk of conditions 
such as stroke in non-
perioperative settings. 
 Thalassaemia is prevalent 
in some parts of Asia and 
iron supplementation 
would not help. 
There will always be exceptions to 
the rule. However, the evidence is 
clear that perioperative iron therapy 
can improve patient outcomes for 
patients with IDA. 
 
Hb: haemoglobin; IDA: iron-deficiency anaemia; PBM: patient blood management; RBC: red 
blood cell 
 
Postponement of surgery due to preoperative anaemia is usually not well received. 
Hospital administrators are concerned about optimising the utilisation of operating theatres, 
while physicians are resistant to changes to their clinical practice and concerned that delaying 
surgery may result in medical complications. Patients do not want to delay treatment, 
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particularly for major illnesses, and are concerned about the cost and time needed for additional 
visits. Understanding that appropriate changes to current clinical practice can deliver better 
patient care and educating patients on the potential risks and benefits can help to overcome 
these challenges. Physicians should initiate anaemia investigations early, while patients should 
also be informed about the benefits of treating preoperative anaemia. We proposed an 
algorithm for the diagnosis and treatment of preoperative anaemia (Fig. 1).  
Although formal iron studies are needed prior to iron therapy, some tests may not be 
readily available in resource-limited settings. We suggest that an assessment of ferritin together 
with clinical and patient-specific risk factors can identify most IDA cases. When IDA is 
detected early, oral iron supplementation is usually the first-line treatment. Some side effects 
from the use of oral iron include nausea, constipation and vomiting,(4) which may lead to poor 
compliance to treatment. A systematic review has concluded that patients administered with 
intravenous (IV) iron experienced fewer gastrointestinal side effects compared to oral iron 
treatments.(30)  
When time is limited, IV iron infusions can be used to rapidly and effectively replenish 
iron stores without compromising outcomes.(31) However, in patients who urgently require 
reliable and rapid iron replacement, IV iron formulations such as iron sucrose, ferric gluconate, 
iron isomaltoside, low-molecular-weight iron dextran (LMW-ID) or ferric carboxymaltose 
may be better suited, as they allow the slow release of iron with marginal or no toxicity-related 
adverse events.(4,32-34) Incidence rates of adverse drug events were found to be lower with 
modern IV iron formulations, including LMW-ID, than with older high-molecular-weight iron 
dextran preparations.(35) Whereas iron sucrose and ferric gluconate infusions need to be 
administered across several sessions, iron isomaltoside, LMW-ID or ferric carboxymaltose, 
which bind iron more tightly, can replenish total iron deficit in one or two doses.(4,32)  
Page 9 of 27 
 
 
IV iron is applicable in certain instances, including immediately before surgery, post 
trauma, and in cases of inability to tolerate or absorb oral iron, iron loss exceeding absorption 
rates, and late pregnancy.(4) When there is insufficient preoperative time (e.g. trauma and 
emergency surgical cases), postoperative IV iron therapy has also been shown to improve Hb 
recovery with fewer RBC transfusions, shorter LOS and, importantly, fewer infections.(36) 
Clinical evidence (Table III) suggests that the use of IV iron increases the total RBC mass of 
patients undergoing surgery and improves outcomes.(17,37-41) Even in critically ill patients, early 
IV iron therapy raised discharge Hb levels despite lower transfusion triggers (< 7.5 g/dL) 
without compromising safety.(42)  
 
Table III. Improvement in patient outcomes from perioperative IV iron therapy. 
No. Study Description Results 
1 Hip and knee 
surgery, 
2016(37)  
Prospective observational, 
single-centre study; 367 
patients (184 before, 183 
after) 
Before vs. after PBM using EPO and 
IV iron: 
 Transfusion: 3% vs. 13%; p = 
0.0003 
 Severe (Hb < 10 g/dL) anaemia at 
discharge 14% vs 25%; p = 0.01 
TSAT 11.0% vs. 0.1%; p < 0.001  
2 Abdominal 
surgery, 
2016(38) 
 
RCT; 72 Australian 
patients with IDA were 
randomly assigned to 
receive either (1) IV iron 
or (2) usual care 
IV iron vs. usual care:
 Transfusion: 12.5% vs. 31.3% 
(60% reduction in RBC transfusion) 
 LOS: 7.0 days vs 9.7 days; p = 
0.026 
 Hb: improved by 0.8 g/dL vs. 0.1 
g/dL by the day of admission; p = 0.01 
 Hb: 1.9 g/dL vs 0.9 g/dL; p = 0.01 
3 Colon cancer, 
2014(39)  
 
ROS; a total of 266 
patients undergoing 
elective surgery were 
included: (1) 111 received 
FCM (median dose 1,000 
mg) and (2) 155 were non-
IV iron subjects 
 
IV iron (FCM) vs. non-IV iron: 
 Transfusion: 9.9% vs. 38.7%; OR 
5.9; p < 0.001 
 LOS: 8.4 ± 6.8 days vs. 10.9 ± 12.4 
days; p < 0.001. 
 % with normalised Hb (30 days 
post surgery): 40.0% vs. 26.7%; p < 
0.05  
 Re-interventions and post-surgery 
complications: 20.7% vs. 26.5%; p = 
0.311 
 Hb (% of responders): 
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48.1% vs. 20.0%; p < 0.0001 at 
admission 
80.0% vs. 48.9%; p < 0.0001 at 30 
days post surgery 
4 Cardiac 
surgery, 
2015(40) 
ROS; 2,662 patients 
analysed, 387 in the pre-
PBM and 2,275 in the 
PBM epoch  
Post-PBM vs. pre-PBM:
 Transfusion: 20.8% vs. 39.3%; p < 
0.001 
 LOS: 10.4 ± 8.0 days vs. 12.2 ± 9.6 
days; p < 0.001 
Hospital mortality rate and cerebral 
vascular accident incidence remained 
unchanged 
 
5 Orthopaedic 
surgery, 
2014(17) 
ROS; 1,534 patients 
undergoing major elective 
hip, knee or spine surgery 
from 17 centres in 6 
European countries  
 
PBM (n = 7) vs. non-PBM centres:  
 Preoperative anaemia: 8.0% vs. 
18.5%; p < 0.001  
 Ferritin: 11.0% vs. 2.6%, TSAT 
11.0% vs. 0.1%; p < 0.001 
  
6 Lower-limb 
arthroplasty, 
2014(41) 
ROS; 2,547 patients 
undergoing elective lower-
limb arthroplasty (n = 
1,186) or hip fracture 
repair (n = 1,361) were 
compared; patients 
received either (1) very-
short-term perioperative 
IV iron (200–600 mg, n = 
1,538), with or without 
recombinant human EPO 
(40,000 IU), or (2) 
standard treatment (n = 
1,009) 
Perioperative IV iron vs. standard 
treatment: 
Hip fracture patients 
 Transfusion: 32.4% vs. 48.8%; p = 
0.001)  
 LOS: 11.9 days vs. 13.4 days; p = 
0.001 
 PNI: 10.7% vs. 26.9%; p = 0.001 
 30-day mortality: 4.8% vs. 9.4%; p 
= 0.003 
Arthroplasty patients 
 Transfusion: 8.9% vs. 30.1%; p = 
0.001 
 LOS: 8.4 days vs. 10.7 days; p = 
0.001 
No differences in PNI rates and 30-
day mortality 
EPO: erythropoietin; FCM: ferric carboxymaltose; Hb: haemoglobin; IDA: iron-deficiency 
anaemia; IV: intravenous; LOS: length of hospital stay; PBM: patient blood management; 
PNI: postoperative nosocomial infections; RBC: red blood cell; RCT: randomised controlled 
trial; ROS: retrospective observational study 
 
EXPERIENCE IN THE ASIA-PACIFIC 
PBM champions such as national health authorities and/or blood services, professional medical 
organisations, hospital administrators and, crucially, physicians are pivotal in promoting PBM 
implementation. They provide the strong leadership needed to sustainably establish effective 
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programmes and create collaborative environments for healthcare professionals from the 
surgical, medical, transfusion medicine, and nursing departments, laboratory and pharmacy 
with guidelines, communication tools and education.(43) We herein discuss examples from 
Australia and Singapore, the Republic of Korea and Malaysia and illustrate how different PBM 
champions can positively influence the practice of PBM in their respective countries. 
 
National health authorities 
In Australia, the National Blood Authority has published comprehensive PBM guidelines since 
2012.(24) In addition, the Australian Commission on Safety and Quality in Health Care 
“requires that blood and blood product policies, procedures and/or protocols are consistent 
with national evidence-based guidelines for pre-transfusion practices, prescribing and clinical 
use of blood and blood products” (Action 7.1.1).(24) From mid-2010 to mid-2015, the number 
of RBC units issued saw a 15.8% reduction.(44) A multidisciplinary National Patient Blood 
Management Collaborative, led by the Department of Health, Australia, was established in 
2015 to further promote appropriate care for patients and reduce exposure to transfusion. 12 
hospitals were selected and supported with federal funding. They identified and implemented 
changes in preoperative practice in areas that were at risk for anaemia. Monthly data for 8,758 
procedures (May 2015–September 2016) showed that 98% of patients were assessed for 
preoperative anaemia, an increase from 90%; 71% had their anaemia managed, up from 28%; 
90% were assessed for ID, from 25%; and 53% had their ID managed, from 39%.(44) 
In Singapore, the Blood Services Group of the Health Sciences Authority, a statutory 
board of the Ministry of Health, supplies blood nationwide. With an ageing population (11.8% 
were aged > 65 years) and life expectancy of 82.7 years, blood demand is expected to increase 
even as eligible donors decrease.(45) To mitigate this, the Ministry of Health and Blood Services 
Group have actively promoted PBM at public hospitals since 2013. Regular national audits of 
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PBM-related efforts have been performed since 2017 to promote appropriate clinical 
indications for RBC transfusion and preoperative anaemia screening for elective surgeries. We 
herein describe these PBM efforts at two major public hospitals: National University Hospital 
and Singapore General Hospital, Singapore. 
National University Hospital’s anaemia clinic was started in 2014 and is integral to its 
PBM programme. A preliminary survey showed that 23% of patients had preoperative 
anaemia, with 57% requiring transfusion subsequently, compared to 18% for patients without 
anaemia. Surgeons were encouraged to refer patients for anaemia management if patients had 
Hb < 10 g/dL, any degree of anaemia and poor cardiopulmonary reserve; or when the surgery 
had a potential for high blood loss. IDA management was initiated with oral iron if ferritin < 
100 μg/L (< 200 μg/L in non-dialysis-dependent chronic kidney disease) and transferrin 
saturation < 20%. IV iron was given as soon as was feasible if there was: no response after two 
weeks, intolerance to oral iron or the surgery was scheduled within four weeks; or after surgery 
if therapy was not started earlier. EPO was used on an individualised basis, e.g. chronic kidney 
disease Stage III/V or chemotherapy-induced anaemia in a palliative setting. 
At Singapore General Hospital, formal PBM implementation was started in 2013 as 
part of the national initiative. The hospital had a number of existing measures to support PBM, 
i.e. a multidisciplinary blood transfusion committee, transfusion guidelines and an early 
preoperative anaemia assessment clinic. In August 2017, a preoperative anaemia management 
pathway was instituted in which anaemic patients undergoing surgery were given either oral 
iron (ferrous fumarate) or single-dose IV iron (ferric carboxymaltose) depending on the 
severity of anaemia, invasiveness of surgery and time available for optimisation. Mandatory 
documentation of indications for RBC transfusion was also instituted, while inappropriate 
indications generated alerts via the computerised physician order entry (CPOE) system. A 
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preliminary one-month audit of the system showed that 21% of CPOEs generated alerts for 
inappropriate indications and were subsequently cancelled.  
 
Professional medical organisations 
The Korean Research Society of Transfusion Alternatives of the Republic of Korea began 
promoting PBM in 2006. In 2014, the Korean Patient Blood Management (KPBM) Research 
Group was formed to further promote greater PBM use. Its active participation saw PBM 
included in the Korean Transfusion Guidelines of 2016 for the first time. In 2016, the KPBM 
organised a new steering committe comprising > 40 leading physicians from various specialties 
to promote PBM in their respective clinical fields.  
The Korean Society of Blood Transfusion, representing practitioners in blood banking 
and transfusion medicine, including laboratory physicians, haematologists and anaesthetists, 
supported PBM with the creation of its PBM committee in 2016. A KPBM survey showed that 
70%–80% of practising surgeons supported the use of PBM and had held special PBM 
symposia within their respective society meetings. A number of Korean hospitals that adopted 
PBM as part of their clinical practice have already demonstrated its benefits in improved 
postoperative Hb levels, with reductions in transfusions (Table IV).(46-49) 
 
Table IV. Studies documenting benefits of PBM in Asia-Pacific countries. 
Yr Country, 
study 
Description Results 
2016 Australia, 
abdominal 
surgery(38) 
 
RCT; 72 patients with IDA 
were randomly assigned to 
receive either (1) IV iron 
or (2) usual care 
IV iron vs. usual care:
 Transfusion: 12.5% vs. 31.3% 
(60% reduction in RBC 
transfusion) 
 LOS: 7.0 days vs. 9.7 days; p 
= 0.026 
 Hb: improved by 0.8 g/dL vs. 
0.1 g/dL by the day of admission; 
p = 0.01 
 Hb: 1.9 g/dL vs 0.9 g/dL; p = 
0.01 
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2016 Australia, 
intensive 
care(42) 
RCT; of 140 patients 
enrolled, (1) 70 were 
assigned to IV iron and (2) 
70 to placebo 
IV iron vs. placebo: 
 Transfusion: 97 vs. 136 red 
blood cell units yielding an 
incidence rate ratio of 0.71 (95% 
CI 0.43–1.18); p = 0.19 
 Median Hb at discharge: 107 
(IQR 97–115) g/L vs. 100 (IQR 
89–111) g/L; p = 0.02 
No significant difference 
between the groups in any safety 
outcome 
2015 Republic of 
Korea, 
obstetrics and 
gynaecology(46) 
Retrospective analysis 
over a 10-year time frame 
of severely anaemic 
women (Hb < 50 g/L) with 
benign conditions who had 
requested not to receive a 
blood transfusion and 
given IV iron and EPO 
instead. Women were 
analysed in two groups: 
(1) a gynaecologic (gyn, n 
= 12) and (2) an obstetric 
(ob, n = 7) population.  
Mean age 35.8 ± 10.2 yr 
With IV iron, EPO and no 
transfusion,  mean Hb 
concentration 41.3 ± 9.7 g/L 
(gyn) and 36.0 ± 8.9 g/L (ob) to 
67.3 ± 14.3 g/L and 73.1 ± 6.9 
g/L, respectively, by the time of 
hospital discharge 
No deaths or other serious 
complications 
2014 Republic of 
Korea, gastric 
cancer(49) 
Case-control study of 2078 
gastric cancer patients who 
underwent surgery 
between February 2007 
and August 2009, 368 
patients developed 
postoperative anaemia (Hb 
level < 9 g/dL) within the 
first postoperative week. 
Patients requiring 
transfusions were 
excluded. (1) IV-iron was 
administered to 63 patients 
(iron group). (2) 60 
patients were observed 
without treatment 
(observation group). 
IV-iron vs. observation group 
 Change in Hb level: 0.648 ± 
0.054 g/dL vs 0.349 ± 0.038 
g/dL; p < 0.001  
 Hb Level 1 and 3 mth 
postoperatively: 10.7 ± 1.3 g/dL 
to 11.9 ± 1.3 g/dL; p = 0.033 vs. 
10.1 ± 1.0 g/dL to 10.8 ± 1.4 
g/dL; p < 0.001 
 Postoperative LOS: 10.5 ± 6.8 
days vs. 7.6 ± 5.5 days; p = 0.011 
No significant differences in 
major and surgical complications 
between the groups (6.3% vs. 
13.3%, p = 0.192; 9.5% vs. 3.3%, 
p = 0.164) 
2011 Republic of 
Korea, bilateral 
total knee 
replacement 
arthroplasty(47)  
RCT; 108 iron-deficient 
patients were randomly 
assigned to: (1) Group IE 
(200 mg of iron sucrose 
intravenously over 1 hr 
and 3,000 IU of 
recombinant human EPO-
beta subcutaneously 
during operation and 
IV iron (Group IE) vs. control 
(Group C): 
 Transfusion: 20.4% vs. 53.7%; 
p = 0.011 
 Mean number of RBC units 
transfused: 0.2 ± 0.5 vs. 0.8 ± 
0.8; p = 0.005  
 Postoperative iron, ferritin, 
and transferrin saturation levels 
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during the postoperative 
period if the Hb level was 
70–80 g/L) or (2) Group C 
(control)  
were significantly higher 
2011 Republic of 
Korea, valvular 
heart 
surgery(48)  
RCT; 74 patients with 
preoperative anaemia were 
randomly allocated to 
either the (1) EPO group 
(500 IU/kg EPO and 200 
mg iron sucrose 
intravenously 1 day before 
the surgery) or (2) control 
group with equivalent 
volume of normal saline 
IV iron vs. control: 
 Transfusion: 22 patients 
(59%) vs. 32 patients (86%); p = 
0.009 
 Mean no. of units of packed 
erythrocytes transfused per 
patient: (3.3 ± 2.2 units/patient 
vs. 1.0 ± 1.1 units/patient; p = 
0.001 
 Reticulocyte count was 
significantly greater on 
postoperative days 4 (p = 0.001) 
and 7 (p = 0.001) 
CI: confidence interval; EPO: erythropoietin; Hb: haemoglobin; IDA: iron-deficient anaemia; 
IQR: interquartile ratio; IV: intravenous; LOS: length of hospital stay; PPA: postpartum 
anaemia; RBC: red blood cell; RCT: randomised controlled trial 
 
Physicians 
In Malaysia, PBM is practiced at the local level (e.g. maternal and foetal medicine department 
at the Sultan Haji Ahmad Shah Hospital, Pahang, Malaysia). Postpartum haemorrhage (PPH) 
remains one of the main causes of maternal mortality in Malaysia. High parity is common 
among local women and access to affordable healthcare remains a key challenge. Women at 
high risk of anaemia are tested for Hb levels and ferritin in early pregnancy. Patients who are 
found to be iron-deficient are treated with low-dose elemental iron (20–80 mg daily); those 
with anaemia are given higher-dose elemental iron orally (100–200 mg daily) and their 
response is monitored. In this resource-constrained setting, IV iron is used when time is limited 
or when oral iron is ineffective or poorly tolerated. Despite its efficacy, IV iron is used 
sparingly due to the higher cost of iron sucrose compared to oral iron. Other practical measures 
to minimise the risk of anaemia included providing dietary advice and advice on increasing the 
interval period between pregnancies as well as treating comorbidities.  
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For postpartum haemorrhage, patients who were not actively bleeding were managed 
in the following ways based on their Hb levels: (a) > 9 g/L – transfusion was deemed 
inappropriate and discouraged; (b) 7–9 g/L – transfusion was based on the need to relieve 
clinical signs and symptoms of anaemia, and the availability of anaemia treatment, expected 
delivery date and risk factors for haemorrhage; and (b) < 7 g/L – transfusion could be used but 
might not be required for well-compensated patients, or other therapies were available. When 
indicated, a single RBC unit was given followed by clinical assessment to determine further 
need. 
 
BENEFITS OF PBM PILLAR 1 
Our article has described the practice of PBM in four different healthcare settings. Although 
these examples are certainly not exhaustive, they illustrate a range of implementation 
approaches that can be applied in both developed and developing countries. As we and others 
have noted, there is an urgent need for action.(50) The anaemia burden in the Asia-Pacific region 
is high, with growing numbers of elderly patients who are more likely to be anaemic.(2) Without 
PBM, a third to half (30%–54%)(16,18,47) of patients undergoing surgery could require  
transfusion, increasing the demand for blood and potentially leading to poorer patient 
outcomes. Shrinking blood donor pools puts a strain on the blood supply system and may result 
in cancellation or postponement of elective surgery in some countries.  
On the other hand, studies in the region have shown that the application of PBM Pillar 
1 has led to shorter LOS, improved Hb/ferritin levels and fewer adverse events, besides reduced 
transfusion rates (Table IV).(38,42,46-49) Implementation of PBM also has a significant positive 
impact on healthcare costs. A 2012 study of > 100,000 patients in the canton of Zurich, 
Switzerland, showed a 27% reduction in RBC transfusion in the first year of implementation 
with direct savings of USD 2.0 million on blood products alone.(43,51) In Australia, the National 
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Blood Authority estimated that a 5% reduction in RBC use would save AUD 14.6 million 
nationally.(51) Cost savings from the use of IV iron to treat preoperative IDA were reported at 
USD 730 per patient (Singapore)(52) and USD 22,192 per quality-adjusted life-year for patients 
with chronic heart failure (Republic of Korea)(53) in 2014. There is also the intangible cost of 
RBC transfusion-associated adverse outcomes and prolonged LOS.(54)  
While each country may face different challenges in implementing PBM, the concept 
is applicable everywhere. Notwithstanding its urgency, the implementation process should 
proceed stepwise in a manner that is appropriate to the healthcare setting and acceptable to 
stakeholders. Post implementation, it is also essential to apply quality assurance measures of 
good benchmarking, monitoring and feedback,(54) and demonstrate improved patient outcomes 
and safety benefits. Although this review presents PBM Pillar 1 for perioperative settings, the 
same principles of implementation can be extended to the other two pillars of PBM and to the 
non-surgical fields of medicine. 
 
CONCLUSION 
IDA is common and it is an independent modifiable risk factor for patient outcomes. Physicians 
and patients need to be aware of the risks of preoperative anaemia and appreciate that early 
treatment of IDA preoperatively can help to improve patient safety and outcomes. The most 
feasible way of implementing PBM is to start with small steps and expand efforts over time. 
Getting PBM Pillar 1 right by using iron replacement therapy to preoperatively optimise red 
cell mass in patients with IDA is a sensible first step to take when embarking on PBM 
implementation, regardless of the healthcare setting. 
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FIGURE 
 
Fig. 1 Proposed algorithm to evaluate and treat perioperative anaemia. *If TSAT is unavailable, 
assess clinical context for conditions that may falsely elevate ferritin despite ID. §If ferritin is 
> 100 μg/L, TSAT < 20% is required to support diagnosis of IDA. If anaemia cannot be 
classified based on these, contact a haematologist. CRP: C-reactive protein; eGFR: estimated 
glomerular filtration rate; EPO: erythropoietin; F: female; Hb: haemoglobin; ID: iron 
deficiency; IDA: iron-deficiency anaemia; IV: intravenous; M: male; TSAT: transferrin 
saturation 
 
